CoChat

Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia

Open access
Salvadó, Gemma, Grothe, Michel J., Groot, Colin, Moscoso, Alexis, Schöll, Michael, Gispert, Juan Domingo, Ossenkoppele, Rik, for the Alzheimer’s Disease Neuroimaging Initiative · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
Cited by 52

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Purpose: To examine associations between the APOE-ε2 and APOE-ε4 alleles and core Alzheimer’s disease (AD) pathological hallmarks as measured by amyloid-β (Aβ) and tau PET in older individuals without dementia. Methods: We analyzed data from 462 ADNI participants without dementia who underwent Aβ ([18 F]florbetapir or [18 F]florbetaben) and tau ([18 F]flortaucipir) PET, structural MRI, and cognitive testing. Employing APOE-ε3 homozygotes as the reference group, associations between APOE-ε2 and APOE-ε4 carriership with global Aβ PET and regional tau PET measures (entorhinal cortex (ERC), inferior temporal cortex, and Braak-V/VI neocortical composite regions) were investigated using linear regression models. In a subset of 156 participants, we also investigated associations between APOE genotype and regional tau accumulation over time using linear mixed models. Finally, we assessed whether Aβ mediated the cross-sectional and longitudinal associations between APOE genotype and tau. Results: Compared to APOE-ε3 homozygotes, APOE-ε2 carriers had lower global Aβ burden (β std [95% confidence interval (CI)]: − 0.31 [− 0.45, − 0.16], p = 0.034) but did not differ on regional tau burden or tau accumulation over time. APOE-ε4 participants showed higher Aβ (β std [95%CI]: 0.64 [0.42, 0.82], p < 0.001) and tau burden (β std range: 0.27-0.51, all p < 0.006). In mediation analyses, APOE-ε4 only retained an Aβ-independent effect on tau in the ERC. APOE-ε4 showed a trend towards increased tau accumulation over time in Braak-V/VI compared to APOE-ε3 homozygotes (β std [95%CI]: 0.10 [− 0.02, 0.18], p = 0.11), and this association was fully mediated by baseline Aβ. Conclusion: Our data suggest that the established protective effect of the APOE-ε2 allele against developing clinical AD is primarily linked to resistance against Aβ deposition rather than tau pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-021-05192-8

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. Jack CR, Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, et al. Age, sex, and APOE ϵ4 effects on memory, brain structure, and β-Amyloid across the adult life Span. JAMA Neurol. 2015;72:511–9. · DOI · Paper page
  2. Oyama F, Shimada H, Oyama R, Ihara Y. Apolipoprotein E genotype, Alzheimer’s pathologies and related gene expression in the aged population. Mol Brain Res. 1995;29:92–8. · DOI
  3. Buckley RF, Mormino EC, Chhatwal J, Schultz AP, Rabin JS, Rentz DM, et al. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. Neurobiol Aging. 2019;78:178–85. · DOI · Paper page
  4. Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without β-amyloid. Neurobiol Aging. Elsevier Inc. 2016;37:19–25. · DOI · Paper page
  5. Grothe MJ, Villeneuve S, Dyrba M, Bartrés-Faz D, Wirth M. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology. 2017;88:569–76. · DOI · Paper page
  6. Toledo JB, Zetterberg H, Van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, et al. Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138:2701–15. · DOI · Paper page
  7. Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. 18 F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017;9:1212–23. · DOI · Paper page
  8. Leuzy A, Cicognola C, Chiotis K, Saint-Aubert L, Lemoine L, Andreasen N, et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2019;46:1152–63. · DOI · Paper page
  9. Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, et al. Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020:2866–78. · DOI · Paper page
  10. Meyer PF, Pichet Binette A, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77:508–16. · DOI · Paper page
  11. Groot C, Sudre CH, Barkhof F, Teunissen CE, van Berckel BNM, Seo SW, et al. Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease. Neurology. 2018;91:e1851–9. · DOI · Paper page
  12. Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jögi J, et al. Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study. Alzheimer’s Res Ther. 2018;10:1–12. · DOI · Paper page
  13. Wolters EE, Golla SSV, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, et al. A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus. EJNMMI Res. 2018;8:79. · DOI
  14. Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, et al. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019;40:638–51. · DOI
  15. Wolf D, Bocchetta M, Preboske GM, Boccardi M, Grothe MJ. Reference standard space hippocampus labels according to the European Alzheimer’s Disease Consortium-Alzheimer’s Disease Neuroimaging Initiative harmonized protocol: utility in automated volumetry. Alzheimers Dement. United States. 2017;13:893–902. · DOI
  16. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, et al. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6:502–16. · DOI · Paper page
  17. Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, et al. A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517–27. · DOI · Paper page
  18. Hayes AF. In: Little TD, editor. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. 2nd ed. New York: Guilford Press; 2018.
  19. Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease. Neurology. 2018;90:695–703. · DOI · Paper page
  20. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-ε2 and Alzheimer’s disease: genotype influences pathologic phenotype. Neurology. 1997;48:515–9. · DOI · Paper page
  21. Nicoll JAR, Savva GM, Stewart J, Matthews FE, Brayne C, Ince P. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales. Neuropathol Appl Neurobiol. 2011;37:285–94. · DOI · Paper page
  22. Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer’s disease. Ann N Y Acad Sci. 1996;777:166–74. · DOI · Paper page
  23. Sabbagh MN, Malek-Ahmadi M, Dugger BN, Lee K, Sue LI, Serrano G, et al. The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease. BMC Neurol. 2013;13:–7. · DOI
  24. Gispert JD, Monté GC, Suárez-Calvet M, Falcon C, Tucholka A, Rojas S, et al. The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer’s disease but not those of sTREM2. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2017;6:50–9.
  25. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O’Neil JP, et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J Neurol Neurosurg Psychiatry. 2014;85:266–73. · DOI · Paper page
  26. Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol. 2019;85:229–40. · DOI · Paper page
  27. Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review. Alzheimers Res Ther. 2020;12:141. · DOI · Paper page
  28. O’Donoghue MC, Murphy SE, Zamboni G, Nobre AC, Mackay CE. APOE genotype and cognition in healthy individuals at risk of Alzheimer’s disease: a review. Cortex. Elsevier Ltd. 2018;104:103–23. · DOI · Paper page
  29. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” alzheimer’s disease. Ann Neurol. 1999;45:358–68. · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
  30. Musiek ES, Holtzman DM. Origins of Alzheimer’s disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol. 2012;25:715–20. · DOI · Paper page
  31. Weigand AJ, Thomas K, Bangen K, Eglit GM, Delano-Wood L, Gilbert P, et al. APOE interacts with tau PET to influence memory independently of amyloid PET. Alzheimer’s Dement. 2020:1–9. · DOI
  32. Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, et al. Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9:4959–70. · DOI · Paper page
  33. Mofrad RB, Tijms BM, Scheltens P, Barkhof F, van der Flier WM, AM Sikkes S, et al. Sex differences in CSF biomarkers vary by Alzheimer’s disease stage and APOE ε4 genotype. Neurology. 2020;https://doi.org/10.1212/WNL.0000000000010629. · DOI · Paper page
  34. Sundermann E, Panizzon M, Chen X, Andrews M, Galasko D, Banks S. Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone. Biol Sex Diff. 2020:1–10. · DOI · Paper page
  35. Boccardi M, Dodich A, Albanese A, Gayet-Agéron A, Festari C, Ashton Nicholas J, et al. The Strategic Biomarker Roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2020. · doi:10.1007/s00259-021-05549-z

Cited by

See all 52

Metadata

Authors
Salvadó, G., Grothe, M. J., Groot, C., Moscoso, A., Schöll, M., Gispert, J. D., Ossenkoppele, R., & Initiative, F. T. A. D. N.
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2021-02-01
Volume
48
Issue
7
Pages
2212-2224
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W3127021661
Cited by
52
References
46
FWCI
5.87
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Alzheimer Nederland (WE.15-2019-10)
  • Instituto de Salud Carlos III (CP19/00031)
  • Ministerio de Ciencia, Innovación y Universidades (RYC-2013-13054)
  • Knut och Alice Wallenbergs Stiftelse (KAW 2014.0363)
  • Swedish Research Council (2017-02869)
  • Swedish State (ALFGBG-813971)
  • Swedish Alzheimer Foundation (AF-740191)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.